Tiziana Life Sciences (LON:TILS)(NASDAQ:TLSA) chairman Gabriele Cerrone speaks to Proactive's Andrew Scott after data on its StemPrintER breast cancer prognostic test was presented at the American Society of Clinical Oncology Virtual Conference.
He says the study demonstrated 'greater refinement and superiority of StemPrintER' over current market leader Oncotype DX in delivering prognostic information as part of the therapeutic decision-making process in ER+/HER2- breast cancer patients.
Cerrone says the findings are made all the more significant given the move last year by Exact Sciences (NASDAQ:EXAS) which paid $2.8bn to buy out Genomic Health because of its Oncotype DX technology.